{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:10:48Z","timestamp":1792555848287,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"DOI":"10.1007\/s11547-025-02014-x","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T01:37:41Z","timestamp":1745199461000},"page":"1058-1063","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["First clinical application of Comprehensive Motion Management with 1.5T MR-linac on prostate cancer patients treated with radiotherapy: technical aspects and suggested workflow recommendations"],"prefix":"10.1007","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0731-8041","authenticated-orcid":false,"given":"Luca","family":"Nicosia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0645-0251","authenticated-orcid":false,"given":"Michele","family":"Rigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1731-5522","authenticated-orcid":false,"given":"Roberto Giuseppe","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6109-4563","authenticated-orcid":false,"given":"Andrea Gaetano","family":"Allegra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4693-2148","authenticated-orcid":false,"given":"Chiara","family":"De-Colle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4328-0319","authenticated-orcid":false,"given":"Niccol\u00f2","family":"Giaj-Levra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Pastorello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4307-3440","authenticated-orcid":false,"given":"Francesco","family":"Ricchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2044-8035","authenticated-orcid":false,"given":"Ruggero","family":"Ruggieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-8628","authenticated-orcid":false,"given":"Filippo","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"issue":"10196","key":"2014_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Bj\u00f6rnlinger K, Seke M, Agrup M, Fransson P, Tavelin B, Norman D, Zackrisson B, Anderson H, Kjell\u00e9n E, Franz\u00e9n L, Nilsson P (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 394(10196):385\u2013395. https:\/\/doi.org\/10.1016\/S0140-6736(19)31131-6","journal-title":"Lancet"},{"issue":"10","key":"2014_CR2","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","volume":"23","author":"AC Tree","year":"2022","unstructured":"Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Armstrong J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Duffton A, Brand DH, Henderson D, Morrison K, Brown S, Pugh J, Burnett S, Mahmud M, Hinder V, Naismith O, Hall E, van As N, PACE Trial Investigators (2022) Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 23(10):1308\u20131320. https:\/\/doi.org\/10.1016\/S1470-2045(22)00517-4","journal-title":"Lancet Oncol"},{"key":"2014_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.radonc.2019.08.027","volume":"141","author":"P Ghadjar","year":"2019","unstructured":"Ghadjar P, Fiorino C, Munck Af Rosensch\u00f6ld P, Pinkawa M, Zilli T, van der Heide UA (2019) ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer. Radiother Oncol 141:5\u201313. https:\/\/doi.org\/10.1016\/j.radonc.2019.08.027","journal-title":"Radiother Oncol"},{"issue":"19","key":"2014_CR4","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1002\/cncr.34836","volume":"129","author":"JE Leeman","year":"2023","unstructured":"Leeman JE, Shin KY, Chen YH, Mak RH, Nguyen PL, D\u2019Amico AV, Martin NE (2023) Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: a systematic review and meta-analysis. Cancer 129(19):3044\u20133052. https:\/\/doi.org\/10.1002\/cncr.34836","journal-title":"Cancer"},{"issue":"2","key":"2014_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/0284186X.2020.1821090","volume":"60","author":"L Nicosia","year":"2021","unstructured":"Nicosia L, Sicignano G, Rigo M, Figlia V, Cuccia F, De Simone A, Giaj-Levra N, Mazzola R, Naccarato S, Ricchetti F, Vitale C, Ruggieri R, Alongi F (2021) Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy. Acta Oncol 60(2):215\u2013221. https:\/\/doi.org\/10.1080\/0284186X.2020.1821090","journal-title":"Acta Oncol"},{"key":"2014_CR6","doi-asserted-by":"publisher","first-page":"110043","DOI":"10.1016\/j.radonc.2023.110043","volume":"190","author":"L Nicosia","year":"2024","unstructured":"Nicosia L, Ravelli P, Rigo M, Giaj-Levra N, Mazzola R, Pastorello E, Ricchetti F, Allegra AG, Ruggieri R, Alongi F (2024) Prostate volume variation during 1.5T MR-guided adaptive stereotactic body radiotherapy (SBRT) and correlation with treatment toxicity. Radiother Oncol 190:110043. https:\/\/doi.org\/10.1016\/j.radonc.2023.110043","journal-title":"Radiother Oncol"},{"key":"2014_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejmp.2020.09.026","volume":"80","author":"R Ruggieri","year":"2020","unstructured":"Ruggieri R, Rigo M, Naccarato S, Gurrera D, Figlia V, Mazzola R, Ricchetti F, Nicosia L, Giaj-Levra N, Cuccia F, Vitale C, Stavreva N, Pressyanov DS, Stavrev P, Pellegrini R, Alongi F (2020) Adaptive SBRT by 1.5T MR-linac for prostate cancer: on the accuracy of dose delivery in view of the prolonged session time. Phys Med 80:34\u201341. https:\/\/doi.org\/10.1016\/j.ejmp.2020.09.026","journal-title":"Phys Med"},{"key":"2014_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ctro.2022.09.001","volume":"37","author":"R Lawes","year":"2022","unstructured":"Lawes R, Barnes H, Herbert T, Mitchell A, Nill S, Oelfke U, Pathmanathan A, Smith GA, Sritharan K, Tree A, McNair HA, Dunlop A (2022) MRI-guided adaptive radiotherapy for prostate cancer: when do we need to account for intra-fraction motion? Clin Transl Radiat Oncol 37:85\u201388. https:\/\/doi.org\/10.1016\/j.ctro.2022.09.001","journal-title":"Clin Transl Radiat Oncol"},{"key":"2014_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/mp.16798","author":"E Persson","year":"2023","unstructured":"Persson E, Goodwin E, Eiben B, Wetscherek A, Nill S, Oelfke U (2023) Real-time motion-including dose estimation of simulated multi-leaf collimator-tracked magnetic resonance-guided radiotherapy. Med Phys. https:\/\/doi.org\/10.1002\/mp.16798","journal-title":"Med Phys"},{"key":"2014_CR10","doi-asserted-by":"publisher","first-page":"109932","DOI":"10.1016\/j.radonc.2023.109932","volume":"189","author":"G Grimbergen","year":"2023","unstructured":"Grimbergen G, Hackett SL, van Ommen F et al (2023) Gating and intrafraction drift correction on a 1.5T MR-Linac: clinical dosimetric benefits for upper abdominal tumors. Radiother Oncol 189:109932. https:\/\/doi.org\/10.1016\/j.radonc.2023.109932","journal-title":"Radiother Oncol"},{"issue":"2","key":"2014_CR11","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.ijrobp.2018.09.011","volume":"103","author":"M Fast","year":"2019","unstructured":"Fast M, van de Schoot A, van de Lindt T, Carbaat C, van der Heide U, Sonke JJ (2019) Tumor trailing for Liver SBRT on the MR-Linac. Int J Radiat Oncol Biol Phys 103(2):468\u2013478. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.09.011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2014_CR12","doi-asserted-by":"publisher","first-page":"100865","DOI":"10.1016\/j.adro.2021.100865","volume":"7","author":"S Naccarato","year":"2022","unstructured":"Naccarato S, Rigo M, Pellegrini R, Voet P, Akhiat H, Gurrera D, De Simone A, Sicignano G, Mazzola R, Figlia V, Ricchetti F, Nicosia L, Giaj-Levra N, Cuccia F, Stavreva N, Pressyanov DS, Stavrev P, Alongi F, Ruggieri R (2022) Automated planning for prostate stereotactic body radiation therapy on the 1.5T MR-Linac. Adv Radiat Oncol 7(3):100865. https:\/\/doi.org\/10.1016\/j.adro.2021.100865","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"2014_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13014-020-01510-w","volume":"15","author":"F Alongi","year":"2020","unstructured":"Alongi F, Rigo M, Figlia V, Cuccia F, Giaj-Levra N, Nicosia L, Ricchetti F, Sicignano G, De Simone A, Naccarato S, Ruggieri R, Mazzola R (2020) 1.5T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. Radiat Oncol 15(1):69. https:\/\/doi.org\/10.1186\/s13014-020-01510-w","journal-title":"Radiat Oncol"},{"issue":"8","key":"2014_CR14","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1002\/mp.14230","volume":"47","author":"TD Keiper","year":"2020","unstructured":"Keiper TD, Tai A, Chen X, Paulson E, Lathuili\u00e8re F, B\u00e9riault S, H\u00e9bert F, Cooper DT, Lachaine M, Li XA (2020) Feasibility of real-time motion tracking using cine MRI during MR-guided radiation therapy for abdominal targets. Med Phys 47(8):3554\u20133566. https:\/\/doi.org\/10.1002\/mp.14230","journal-title":"Med Phys"},{"issue":"5","key":"2014_CR15","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1002\/mp.16342","volume":"50","author":"H Jassar","year":"2023","unstructured":"Jassar H, Tai A, Chen X, Keiper TD, Paulson E, Lathuili\u00e8re F, B\u00e9riault S, H\u00e9bert F, Savard L, Cooper DT, Cloake S, Li XA (2023) Real-time motion monitoring using orthogonal cine MRI during MR-guided adaptive radiation therapy for abdominal tumors on 1.5T MR-Linac. Med Phys 50(5):3103\u20133116. https:\/\/doi.org\/10.1002\/mp.16342","journal-title":"Med Phys"},{"key":"2014_CR16","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1002\/mp.13002","volume":"45","author":"OL Green","year":"2018","unstructured":"Green OL, Rankine LJ, Cai B et al (2018) First clinical implementation of real-time, real anatomy tracking and radiation beam control. Med Phys 45:3728\u20133740. https:\/\/doi.org\/10.1002\/mp.13002","journal-title":"Med Phys"},{"key":"2014_CR17","doi-asserted-by":"publisher","first-page":"1280845","DOI":"10.3389\/fonc.2023.1280845","volume":"13","author":"M Galetto","year":"2023","unstructured":"Galetto M, Nardini M, Capotosti A et al (2023) Motion and dosimetric criteria for selecting gating technique for apical lung lesions in magnetic resonance guided radiotherapy. Front Oncol 13:1280845. https:\/\/doi.org\/10.3389\/fonc.2023.1280845","journal-title":"Front Oncol"},{"key":"2014_CR18","doi-asserted-by":"publisher","first-page":"1325105","DOI":"10.3389\/fonc.2023.1325105","volume":"13","author":"J Snyder","year":"2024","unstructured":"Snyder J, Smith B, Aubin JS, Shepard A, Hyer D (2024) Simulating an intra-fraction adaptive workflow to enable PTV margin reduction in MRIgART volumetric modulated arc therapy for prostate SBRT. Front Oncol 13:1325105. https:\/\/doi.org\/10.3389\/fonc.2023.1325105","journal-title":"Front Oncol"},{"issue":"3","key":"2014_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","volume":"9","author":"AU Kishan","year":"2023","unstructured":"Kishan AU, Ma TM, Lamb JM, Casado M, Wilhalme H, Low DA, Sheng K, Sharma S, Nickols NG, Pham J, Yang Y, Gao Y, Neylon J, Basehart V, Cao M, Steinberg ML (2023) Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial. JAMA Oncol 9(3):365\u2013373. https:\/\/doi.org\/10.1001\/jamaoncol.2022.6558","journal-title":"JAMA Oncol"},{"issue":"1","key":"2014_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13014-020-01622-3","volume":"15","author":"F Cuccia","year":"2020","unstructured":"Cuccia F, Mazzola R, Nicosia L, Figlia V, Giaj-Levra N, Ricchetti F, Rigo M, Vitale C, Mantoan B, De Simone A, Sicignano G, Ruggieri R, Cavalleri S, Alongi F (2020) Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5T MR-guided stereotactic body radiotherapy. Radiat Oncol (London, England) 15(1):178. https:\/\/doi.org\/10.1186\/s13014-020-01622-3","journal-title":"Radiat Oncol (London, England)"},{"key":"2014_CR21","doi-asserted-by":"publisher","first-page":"1379596","DOI":"10.3389\/fonc.2024.1379596","volume":"14","author":"RL Westley","year":"2024","unstructured":"Westley RL, Alexander SE, Goodwin E et al (2024) Magnetic resonance image-guided adaptive radiotherapy enables safe CTV-to-PTV margin reduction in prostate cancer: a cine MRI motion study. Front Oncol 14:1379596. https:\/\/doi.org\/10.3389\/fonc.2024.1379596","journal-title":"Front Oncol"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-025-02014-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-025-02014-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-025-02014-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T10:41:42Z","timestamp":1752576102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-025-02014-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["2014"],"URL":"https:\/\/doi.org\/10.1007\/s11547-025-02014-x","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Filippo Alongi is consultant for Elekta and received speaker honoraria. Ruggero Ruggieri is scientific consultant for Elekta and received speaker honoraria. Roberto G. Pellegrini is an employee of Elekta.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients signed an informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The study didn\u2019t require ethics committee approval.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}